Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dyadic International ( (DYAI) ) just unveiled an update.
On July 17, 2025, Dyadic International received a deficiency notice from Nasdaq due to its securities not maintaining the minimum bid price of $1 per share for 30 consecutive business days. The company has until January 13, 2026, to regain compliance, failing which it may face delisting, although it can appeal the decision. Additionally, Dyadic is also out of compliance with the minimum Market Value of Listed Securities requirement, with a deadline of December 20, 2025, to rectify this issue.
The most recent analyst rating on (DYAI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Dyadic International stock, see the DYAI Stock Forecast page.
Spark’s Take on DYAI Stock
According to Spark, TipRanks’ AI Analyst, DYAI is a Neutral.
Dyadic International’s overall score reflects significant financial challenges, notably ongoing losses and negative cash flows. While strategic partnerships and revenue growth are positive, they are offset by high leverage and operational inefficiencies. The stock’s technical indicators suggest weak momentum, and its valuation remains unattractive due to unprofitability. The earnings call provides some optimism about future growth, but near-term challenges persist.
To see Spark’s full report on DYAI stock, click here.
More about Dyadic International
Dyadic International, Inc. operates in the biotechnology industry, focusing on the development and production of enzymes and other proteins for various markets, including pharmaceuticals, biofuels, and industrial enzymes.
Average Trading Volume: 51,631
Technical Sentiment Signal: Sell
Current Market Cap: $29.49M
See more insights into DYAI stock on TipRanks’ Stock Analysis page.